BIIB-2014.9.30-10Q


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
 
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2014
OR
 
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 0-19311
BIOGEN IDEC INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
33-0112644
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
225 Binney Street, Cambridge, MA 02142
(617) 679-2000
(Address, including zip code, and telephone number, including
area code, of registrant’s principal executive offices)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files):    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check One):
Large accelerated filer x
 
Accelerated filer o
Non-accelerated filer o
 
Smaller reporting company  o
(Do not check if a smaller reporting company)
 
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):    Yes  o    No  x
The number of shares of the issuer’s Common Stock, $0.0005 par value, outstanding as of October 17, 2014, was 236,155,407 shares.
 




Table of Contents

BIOGEN IDEC INC.
FORM 10-Q — Quarterly Report
For the Quarterly Period Ended September 30, 2014
TABLE OF CONTENTS
 
 
 
Page
 
 
 
Item 1.
Financial Statements (unaudited)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Item 2.
 
 
 
Item 3.
 
 
 
Item 4.
 
PART II — OTHER INFORMATION
 
 
 
Item 1.
 
 
 
Item 1A.
 
 
 
Item 2.
 
 
 
Item 6.
 
 


2

Table of Contents

NOTE REGARDING FORWARD-LOOKING STATEMENTS
This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the “Act”) with the intention of obtaining the benefits of the “Safe Harbor” provisions of the Act. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will” and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:
the anticipated amount, timing and accounting of revenues, contingent payments, milestone, royalty and other payments under licensing, collaboration or acquisition agreements, tax positions and contingencies, collectability of receivables, pre-approval inventory, cost of sales, research and development costs, compensation and other expenses, amortization of intangible assets, foreign currency forward contracts and impairment assessments;
the potential impact of increased product competition in the multiple sclerosis (MS) and hemophilia markets;
the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, sales and promotional practices, product liability and other matters;
the expected resolution and financial impact of our dispute with the Italian National Medicines Agency relating to sales of TYSABRI for the periods from February 2009 through January 2013;
the costs, timing, potential approval and therapeutic scope of the development and commercialization of our pipeline products and the expected timing of launch of recently approved products;
our intent to commit resources for research and development opportunities;
the potential impact of healthcare reform in the U.S., implementation of provisions of the Affordable Care Act, and measures being taken worldwide designed to reduce healthcare costs to constrain the overall level of government expenditures, including the impact of pricing actions in Europe and elsewhere, and reduced reimbursement for our products;
our ability to finance our operations and business initiatives and obtain funding for such activities; and
the impact of new laws and accounting standards.
These forward-looking statements involve risks and uncertainties, including those that are described in the “Risk Factors” section of this report and elsewhere within this report that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. We do not undertake any obligation to publicly update any forward-looking statements.
NOTE REGARDING COMPANY AND PRODUCT REFERENCES
Throughout this report, “Biogen Idec,” the “Company,” “we,” “us” and “our” refer to Biogen Idec Inc. and its consolidated subsidiaries. References to “RITUXAN” refer to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan), and “ANGIOMAX” refers to both ANGIOMAX (the trade name for bivalirudin in the U.S., Canada and Latin America) and ANGIOX (the trade name for bivalirudin in Europe).
NOTE REGARDING TRADEMARKS
ALPROLIX®, AVONEX®, RITUXAN®, TECFIDERA®, and TYSABRI® are registered trademarks of Biogen Idec. ELOCTATM, ELOCTATETM, FUMADERMTM, PLEGRIDYTM and ZINBRYTATM are trademarks of Biogen Idec. The following are trademarks of the respective companies listed: ANGIOMAX® and ANGIOXTM — The Medicines Company; ARZERRA® — Glaxo Group Limited; BENLYSTA® — GlaxoSmithKline Intellectual Property Limited; BETASERON®— Bayer Pharma AG; EXTAVIA® — Novartis AG; FAMPYRATM — Acorda Therapeutics, Inc.; GAZYVA® —  Genentech, Inc.; and REBIF® — Ares Trading S.A.

3

Table of Contents

PART I FINANCIAL INFORMATION

BIOGEN IDEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited, in thousands, except per share amounts)
 
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
 
2014
 
2013
 
2014
 
2013
Revenues:
 
 
 
 
 
 
 
Product, net
$
2,117,366

 
$
1,453,554

 
$
5,916,423

 
$
3,935,251

Unconsolidated joint business
290,678

 
303,210

 
890,859

 
856,601

Other
103,402

 
71,016

 
255,367

 
174,497

Total revenues
2,511,446

 
1,827,780

 
7,062,649

 
4,966,349

Cost and expenses:
 
 
 
 
 
 
 
Cost of sales, excluding amortization of acquired intangible assets
302,639

 
234,696

 
873,771

 
599,173

Research and development
417,174

 
410,017

 
1,393,331

 
1,021,820

Selling, general and administrative
570,436

 
405,584

 
1,658,732

 
1,189,194

Amortization of acquired intangible assets
122,431

 
99,998

 
382,515

 
233,524

Collaboration profit sharing

 

 

 
85,357

(Gain) loss on fair value remeasurement of contingent consideration
(49,433
)
 
(97
)
 
(46,213
)
 
(2,983
)
Total cost and expenses
1,363,247

 
1,150,198

 
4,262,136

 
3,126,085

Gain on sale of rights
4,379

 
6,949

 
12,138

 
17,319

Income from operations
1,152,578

 
684,531

 
2,812,651

 
1,857,583

Other income (expense), net
(16,290
)
 
(4,640
)
 
(17,030
)
 
(29,525
)
Income before income tax expense and equity in loss of investee, net of tax
1,136,288

 
679,891

 
2,795,621

 
1,828,058

Income tax expense
274,774

 
186,105

 
721,709

 
410,753

Equity in loss of investee, net of tax
5,394

 
6,170

 
14,932

 
12,270

Net income
856,120

 
487,616

 
2,058,980

 
1,405,035

Net income (loss) attributable to noncontrolling interests, net of tax
(738
)
 

 
7,660

 

Net income attributable to Biogen Idec Inc.
$
856,858

 
$
487,616

 
$
2,051,320

 
$
1,405,035

Net income per share:
 
 
 
 
 
 
 
Basic earnings per share attributable to Biogen Idec Inc.
$
3.63

 
$
2.06

 
$
8.67

 
$
5.93

Diluted earnings per share attributable to Biogen Idec Inc.
$
3.62

 
$
2.05

 
$
8.64

 
$
5.89

Weighted-average shares used in calculating:
 
 
 
 
 
 
 
Basic earnings per share attributable to Biogen Idec Inc.
236,217

 
237,070

 
236,641

 
237,131

Diluted earnings per share attributable to Biogen Idec Inc.
236,972

 
238,349

 
237,449

 
238,508







See accompanying notes to these unaudited condensed consolidated financial statements.

4

Table of Contents

BIOGEN IDEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(unaudited, in thousands)
 
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
 
2014
 
2013
 
2014
 
2013
Net income attributable to Biogen Idec Inc.
$
856,858

 
$
487,616

 
$
2,051,320

 
$
1,405,035

Other comprehensive income:
 
 
 
 
 
 
 
Unrealized gains (losses) on securities available for sale, net of tax of $(6) and $3,639 for the three months ended September 30, 2014 and 2013, respectively; and $(3,021) and $6,554 for the nine months ended September 30, 2014 and 2013, respectively
12

 
6,211

 
(5,127
)
 
11,171

Unrealized gains (losses) on foreign currency forward contracts, net of tax of $302 and $(298) for the three months ended September 30, 2014 and 2013, respectively; and $307 and $1,182 for the nine months ended September 30, 2014 and 2013, respectively
48,242

 
(14,847
)
 
64,793

 
(5,549
)
Unrealized gains (losses) on pension benefit obligation
691

 
892

 
1,338

 
3,167

Currency translation adjustment
(60,254
)
 
33,564

 
(71,246
)
 
17,201

Total other comprehensive income (loss), net of tax
(11,309
)
 
25,820

 
(10,242
)
 
25,990

Comprehensive income attributable to Biogen Idec Inc.
845,549

 
513,436

 
2,041,078

 
1,431,025

Comprehensive income (loss) attributable to noncontrolling interests, net of tax
(738
)
 

 
7,660

 

Comprehensive income
$
844,811

 
$
513,436

 
$
2,048,738

 
$
1,431,025































See accompanying notes to these unaudited condensed consolidated financial statements.

5

Table of Contents

BIOGEN IDEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands, except per share amounts)
 
 
As of September 30,
2014
 
As of December 31,
2013
ASSETS
Current assets:
 
 
 
Cash and cash equivalents
$
1,186,281

 
$
602,562

Marketable securities
675,065

 
620,167

Accounts receivable, net
1,091,232

 
824,406

Due from unconsolidated joint business, net
269,999

 
252,662

Inventory
753,063

 
659,003

Other current assets
396,471

 
226,134

Total current assets
4,372,111

 
3,184,934

Marketable securities
1,371,431

 
625,772

Property, plant and equipment, net
1,724,129

 
1,750,710

Intangible assets, net
4,129,754

 
4,474,653

Goodwill
1,541,204

 
1,232,916

Investments and other assets
565,513

 
594,350

Total assets
$
13,704,142

 
$
11,863,335

LIABILITIES AND EQUITY
Current liabilities:
 
 
 
Current portion of notes payable
$
3,220

 
$
3,494

Taxes payable
159,638

 
179,685

Accounts payable
233,629

 
219,913

Accrued expenses and other
1,544,160

 
1,355,187

Total current liabilities
1,940,647

 
1,758,279

Notes payable
583,977

 
592,433

Long-term deferred tax liability
90,357

 
232,554

Other long-term liabilities
658,276

 
659,231

Total liabilities
3,273,257

 
3,242,497

Commitments and contingencies


 


Equity:
 
 
 
Biogen Idec Inc. shareholders’ equity
 
 
 
Preferred stock, par value $0.001 per share

 

Common stock, par value $0.0005 per share
129

 
128

Additional paid-in capital
4,150,007

 
4,023,651

Accumulated other comprehensive loss
(37,987
)
 
(27,745
)
Retained earnings
8,400,455

 
6,349,135

Treasury stock, at cost
(2,084,908
)
 
(1,724,927
)
Total Biogen Idec Inc. shareholders’ equity
10,427,696

 
8,620,242

Noncontrolling interests
3,189

 
596

Total equity
10,430,885

 
8,620,838

Total liabilities and equity
$
13,704,142

 
$
11,863,335



See accompanying notes to these unaudited condensed consolidated financial statements.

6

Table of Contents

BIOGEN IDEC INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in thousands)
 
 
For the Nine Months
Ended September 30,
 
2014
 
2013
Cash flows from operating activities:
 
 
 
Net income
$
2,058,980

 
$
1,405,035

Adjustments to reconcile net income to net cash flows from operating activities:
 
 
 
Depreciation and amortization
530,508

 
373,357

Share-based compensation
119,508

 
104,851

Deferred income taxes
(229,273
)
 
(166,187
)
Other
(95,711
)
 
(36,577
)
Changes in operating assets and liabilities, net:
 
 
 
Accounts receivable
(297,057
)
 
(219,860
)
Inventory
(119,890
)
 
(182,814
)
Accrued expenses and other current liabilities
19,283

 
110,794

Other changes in operating assets and liabilities, net
22,904

 
87,474

Net cash flows provided by operating activities
2,009,252

 
1,476,073

Cash flows from investing activities:
 
 
 
Proceeds from sales and maturities of marketable securities
1,942,871

 
5,025,218

Purchases of marketable securities
(2,738,584
)
 
(2,473,609
)
Acquisition of TYSABRI rights

 
(3,262,719
)
Purchases of property, plant and equipment
(180,854
)
 
(167,628
)
Contingent consideration related to Fumapharm AG acquisition
(175,000
)
 

Other
(13,131
)
 
(15,954
)
Net cash flows used in investing activities
(1,164,698
)
 
(894,692
)
Cash flows from financing activities:
 
 
 
Purchase of treasury stock
(359,981
)
 
(400,308
)
Proceeds from issuance of stock for share-based compensation arrangements
44,960

 
56,367

Repayment of borrowings under senior notes and other debt
(2,674
)
 
(452,340
)
Excess tax benefit from stock options
90,423

 
67,902

Other
(15,336
)
 
670

Net cash flows used in financing activities
(242,608
)
 
(727,709
)
Net increase (decrease) in cash and cash equivalents
601,946

 
(146,328
)
Effect of exchange rate changes on cash and cash equivalents
(18,227
)
 
3,418

Cash and cash equivalents, beginning of the period
602,562

 
570,721

Cash and cash equivalents, end of the period
$
1,186,281

 
$
427,811














See accompanying notes to these unaudited condensed consolidated financial statements.

7

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)


1.
Summary of Significant Accounting Policies
Business Overview
Biogen Idec is a global biotechnology company focused on discovering, developing, manufacturing and marketing therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. We also collaborate on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA for the treatment of chronic lymphocytic leukemia.
Basis of Presentation
In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The information included in this quarterly report on Form 10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2013 (2013 Form 10-K). Our accounting policies are described in the “Notes to Consolidated Financial Statements” in our 2013 Form 10-K and updated, as necessary, in this Form 10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three and nine months ended September 30, 2014, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.
Consolidation
Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are entitled to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation.
In determining whether we are the primary beneficiary of an entity and therefore required to consolidate, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.
 Use of Estimates
The preparation of our condensed consolidated financial statements requires us to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates and judgments and methodologies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.
Property, Plant and Equipment
Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $1,246.4 million and $1,118.3 million as of September 30, 2014 and December 31, 2013, respectively.

8

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

Accounting for Share-Based Compensation
During the nine months ended September 30, 2014, we granted performance-vested restricted stock units under our share-based compensation program, which can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of the Board of Directors. We have classified these awards as a liability as, historically, similar awards have been settled in cash. We record the estimated fair value of PUs as compensation expense over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense, net of forfeitures, over the period from the grant date to the date on which the employee is retirement eligible.
We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our PUs and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with PUs is based upon the share price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the share price and estimated outcome of the performance-related conditions until the date results are determined and settled.
New Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The new standard will be effective for us on January 1, 2017. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.
In June 2014, the FASB issued ASU No. 2014-11, Transfers and Servicing (Topic 860): Repurchase-to-Maturity Transactions, Repurchase Financings, and Disclosure. The new standard expands secured borrowing accounting for repurchase-to-maturity transactions and repurchase financings and sets forth new disclosure requirements for repurchase agreements, securities lending transactions, and repurchase-to-maturity transactions that are accounted for as secured borrowings. The new standard will be effective for us on April 1, 2015. The adoption of this standard is not expected to have an impact on our financial position or results of operations.
2.
Accounts Receivable
Our accounts receivable primarily arise from product sales in the U.S. and Europe and mainly represent amounts due from our wholesale distributors, public hospitals and other government entities. Concentrations of credit risk with respect to our accounts receivable, which are typically unsecured, are limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. The majority of our accounts receivable have standard payment terms which generally require payment within 30 to 90 days. We monitor the financial performance and credit worthiness of our large customers so that we can properly assess and respond to changes in their credit profile. We provide reserves against trade receivables for estimated losses that may result from a customer’s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve. To date, our historical reserves and write-offs of accounts receivable have not been significant.
The credit and economic conditions within Italy, Spain and Portugal, among other members of the E.U. continue to remain uncertain. Uncertain credit and economic conditions have generally led to a lengthening of time to collect our accounts receivable in some of these countries. In Portugal and select regions in Spain and Italy, where our collections have slowed and a significant portion of these receivables are routinely being collected beyond our contractual payment terms and over periods in excess of one year, we have discounted our receivables and reduced related revenues based on the period of time that we estimate those amounts will be paid, to the extent such period exceeds one year, using the country’s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recognized as a component of other income (expense), net within our condensed consolidated statements of income.

9

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, continued)

Our net accounts receivable balances from product sales in selected European countries are summarized as follows:
 
As of September 30, 2014
(In millions)
Current
Balance Included
within Accounts
Receivable, net
 
Non-Current
Balance Included
within Investments
and Other Assets
 
Total
Spain
$
58.2

 
$
10.9

 
$
69.1

Italy
$
68.1

 
$
1.5

 
$
69.6

Portugal
$
19.8

 
$
8.5

 
$
28.3

 
 
As of December 31, 2013
(In millions)
Current
Balance Included
within Accounts
Receivable, net
 
Non-Current
Balance Included
within Investments
and Other Assets
 
Total
Spain
$
113.3

 
$
6.8

 
$
120.1

Italy
$
76.1

 
$
2.4

 
$
78.5

Portugal
$
10.4

 
$
8.2

 
$
18.6

Approximately $17.4 million and $45.9 million of the total net accounts receivable balances for these countries were overdue more than one year as of September 30, 2014 and December 31, 2013, respectively. During the first quarter of 2014, we received approximately $59.6 million in payments from Spain related to receivables aged greater than one year.
Pricing of TYSABRI in Italy - AIFA
In the fourth quarter of 2011, Biogen Idec Italia SRL, our Italian subsidiary, received a notice from the Italian National Medicines Agency (Agenzia Italiana del Farmaco or AIFA) stating that sales of TYSABRI for the period from mid-February 2009 through mid-February 2011 exceeded by EUR30.7 million a reimbursement limit established pursuant to a Price Determination Resolution (Price Resolution) granted by AIFA in December 2006. In December 2011, based on our interpretation that the Price Resolution by its terms only applied to the first 24 months of TYSABRI sales (which began in mid-February 2007), we filed an appeal against AIFA in administrative court in Rome, Italy seeking a ruling that the reimbursement limit does not apply to the periods beginning in mid-February 2009 and that the position of AIFA is unenforceable. That appeal is pending. Since being notified in the fourth quarter of 2011 that AIFA believed a reimbursement limit was in effect, we deferred revenue on sales of TYSABRI as if the reimbursement limit were in effect for each biannual period beginning in mid-February 2009.
In July 2013, we negotiated an agreement in principle with AIFA's Price and Reimbursement Committee that would have resolved all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for the periods from February 2009 through January 2013 for an aggregate repayment of EUR33.3 million. The agreement was sent to the Avvocatura Generale dello Stata (Attorney General) for its opinion. As a result of this agreement in principle, we recorded a liability and reduction to revenue of EUR15.4 million at June 30, 2013. That adjustment approximated 50% of the claim related to the period from February 2009 through January 2011 as the likelihood of making a payment to resolve AIFA's claims for that period was then probable and the amount could be estimated. This agreement in principle was not finalized, and AIFA and Biogen Idec Italia SRL remain in discussions about a resolution relating to the claims at issue in that agreement in principle. We continue to believe that a settlement with AIFA relating to these claims is probable and have retained the EUR15.4 million liability recorded as of June 30, 2013.
In June 2014, AIFA approved a resolution, effective for a 24 month term, setting the price for TYSABRI in Italy. The resolution also eliminated the reimbursement limit from February 2013 going forward. As a result, we recognized $53.5 million of TYSABRI revenues related to the periods beginning February 2013 that were previously deferred. An aggregate amount of $80.9 million remains deferred as of September 30, 2014 related to the periods from mid-February 2011 through January 2013.

10

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, continued)

3.
Reserves for Discounts and Allowances
An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions)
Discounts
 
Contractual
Adjustments
 
Returns
 
Total
Balance, as of December 31, 2013
$
47.0

 
$
335.6

 
$
33.7

 
$
416.3

Current provisions relating to sales in current year
247.8

 
907.3

 
27.3

 
1,182.4

Adjustments relating to prior years
(0.2
)
 
(16.6
)
 
15.4

 
(1.4
)
Payments/credits relating to sales in current year
(200.1
)
 
(603.7
)
 
(1.5
)
 
(805.3
)
Payments/credits relating to sales in prior years
(45.3
)
 
(269.0
)
 
(29.0
)
 
(343.3
)
Balance, as of September 30, 2014
$
49.2

 
$
353.6

 
$
45.9

 
$
448.7

The total reserves above, included in our condensed consolidated balance sheets, are summarized as follows:
(In millions)
As of September 30,
2014
 
As of December 31,
2013
Reduction of accounts receivable
$
119.5

 
$
151.4

Component of accrued expenses and other
329.2

 
264.9

Total reserves
$
448.7

 
$
416.3

4.
Inventory
The components of inventory are summarized as follows:
(In millions)
As of
September 30,
2014
 
As of
December 31,
2013
Raw materials
$
133.8

 
$
115.0

Work in process
478.6

 
435.4

Finished goods
140.7

 
108.6

Total inventory
$
753.1

 
$
659.0

As of September 30, 2014, our inventory includes $5.6 million associated with our ZINBRYTA (Daclizumab High Yield Process) program, which has been capitalized in advance of regulatory approval. As of December 31, 2013, our inventory included $93.7 million associated with our ALPROLIX, ELOCTATE and PLEGRIDY programs, which were capitalized in advance of regulatory approval. ALPROLIX, ELOCTATE and PLEGRIDY were subsequently approved during the nine months ended September 30, 2014.

11

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, continued)

5.
Intangible Assets and Goodwill
Intangible Assets
Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:
 
 
 
As of September 30, 2014
 
As of December 31, 2013
(In millions)
Estimated
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
Cost
 
Accumulated
Amortization
 
Net
Out-licensed patents
13-23 years
 
$
543.3

 
$
(473.8
)
 
$
69.5

 
$
578.0

 
$
(450.8
)
 
$
127.2

Developed 
technology
15-23 years
 
3,005.3

 
(2,339.8
)
 
665.5

 
3,005.3

 
(2,165.4
)
 
839.9

In-process research and development
Indefinite until commercialization
 
314.1

 

 
314.1

 
327.4

 

 
327.4

Trademarks and 
tradenames
Indefinite
 
64.0

 

 
64.0

 
64.0

 

 
64.0

Acquired and in-licensed rights 
and patents
6-17 years
 
3,274.4

 
(257.7
)
 
3,016.7

 
3,240.0

 
(123.8
)
 
3,116.2

Total intangible assets
 
 
$
7,201.1

 
$
(3,071.3
)
 
$
4,129.8

 
$
7,214.7

 
$
(2,740.0
)
 
$
4,474.7

For the three and nine months ended September 30, 2014, amortization of acquired intangible assets totaled $122.4 million and $382.5 million, respectively, as compared to $100.0 million and $233.5 million, respectively, in the prior year comparative periods. For the three months ended September 30, 2014, compared to the same period in 2013, the change in amortization of acquired intangible assets was primarily driven by a $16.2 million impairment loss related to one of our in-process research and development (IPR&D) intangible assets as discussed further below. For the nine months ended September 30, 2014, compared to the same period in 2013, the change in amortization of acquired intangible assets was primarily driven by our acquisition of the TYSABRI rights from Elan Pharma International Ltd. (Elan), total impairment charges of $50.9 million related to one of our out-licensed patents and one of our IPR&D intangible assets and lower expected lifetime revenues of AVONEX as discussed further below.
Out-licensed Patents
Out-licensed patents to third-parties primarily relate to patents acquired in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. During the nine months ended September 30, 2014, we recorded a charge of $34.7 million related to the impairment of one of our out-licensed patents to reflect a change in its estimated fair value, due to a change in the underlying competitive market for that product, which occurred during the first quarter of 2014. The charge is included in amortization of acquired intangibles. The fair value of the intangible asset was based on discounted cash flow calculated using Level 3 fair value measurements and inputs including estimated revenues.
Developed Technology
Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of September 30, 2014 was $656.0 million. We amortize this intangible asset using the economic consumption method based on actual and expected revenues generated from the sales of our AVONEX product.

12

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, continued)

In-process Research and Development (IPR&D)
IPR&D represents the fair value assigned to research and development assets that we acquire that have not reached technological feasibility at the date of acquisition. Upon commercialization, we determine the estimated useful life.
An analysis of anticipated lifetime revenues and anticipated development costs is performed annually during our long- range planning cycle, which was updated in the third quarter of 2014. This analysis is based upon certain assumptions that we evaluate on a periodic basis, including anticipated future product sales, the expected impact of changes in the amount of development costs and the probabilities of our programs succeeding, the introduction of new products by our competitors and changes in our commercial and pipeline product candidates.  
During the three months ended September 30, 2014, we updated the probabilities of success related to the early stage programs acquired through our recent acquisitions. The change in probability of success, combined with a delay in one of the projects, resulted in an impairment loss of $16.2 million in one of our IPR&D assets during the three months ended September 30, 2014. In addition, we have adjusted the value of our contingent consideration liabilities to reflect these lower probabilities of success in connection with these earlier stage programs resulting in net gains of $49.4 million in the three months ended September 30, 2014. The impairment charge was included in amortization of acquired intangible assets and the gains were recorded in (gain) loss on fair value remeasurement of contingent consideration. The fair values of the intangible assets and contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success.
Acquired and In-licensed Rights and Patents
Acquired and in-licensed rights and patents primarily relate to our acquisition of the TYSABRI rights from Elan. The net intangible asset capitalized related to this acquisition was $3,178.3 million. In the second quarter of 2013, we began amortizing this intangible asset over the estimated useful life using an economic consumption method based on actual and expected revenues generated from the sales of our TYSABRI product. The net book value of this asset as of September 30, 2014 was $2,957.4 million. For a more detailed description of this transaction, please read Note 2, Acquisitions to our consolidated financial statements included within our 2013 Form 10-K.
The increase in acquired and in-licensed rights and patents during the nine months ended September 30, 2014, was primarily related to the $20.0 million contingent payment due to the former owners of Syntonix Pharmaceuticals, Inc., which became payable upon the approval of ALPROLIX in the U.S. by the U.S. Food and Drug Administration (FDA) in the first quarter of 2014. We have recorded an additional $7.8 million of acquired in-licensed rights and patents related to this consideration, along with a corresponding deferred tax liability of the same amount.

13

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, continued)

Estimated Future Amortization of Intangible Assets
Our amortization expense is based on the economic consumption of the intangible assets. Our most significant intangible assets are related to our AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of AVONEX and TYSABRI. This analysis is updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.
Our most recent long range planning cycle was updated in the third quarter of 2014. Our analysis included an increase in the expected future product revenues of TYSABRI, resulting in a decrease in amortization expense as compared to prior quarters. Our analysis also included a decrease in the expected future product revenues of AVONEX, resulting in an increase in amortization expense as compared to prior quarters. The results of our TYSABRI and AVONEX analyses were impacted by changes in the estimated impact of TECFIDERA, as well as other existing and potential oral and alternative MS formulations, including PLEGRIDY, that may compete with TYSABRI and AVONEX. Based upon this recent analysis, the estimated future amortization for acquired intangible assets for the balance of 2014 and the next five years is expected to be as follows:
(In millions)
As of September 30, 2014
2014 (remaining three months)
$
104.2

2015
345.2

2016
309.5

2017
285.5

2018
284.5

2019
273.3

Total
$
1,602.2

Goodwill
The following table provides a roll forward of the changes in our goodwill balance:
(In millions)
As of
September 30,
2014
 
As of
December 31,
2013
Goodwill, beginning of period
$
1,232.9

 
$
1,201.3

Increase to goodwill
308.3

 
35.7

Other

 
(4.1
)
Goodwill, end of period
$
1,541.2

 
$
1,232.9

The increase in goodwill during the nine months ended September 30, 2014 was related to $350.0 million in contingent payments (exclusive of $41.7 million in tax benefits) as we reached the $2.0 billion cumulative sales level related to FUMADERM and TECFIDERA (together, Fumapharm Products) during the second quarter of 2014 and the $3.0 billion cumulative sales level related to Fumapharm Products during the third quarter of 2014. For additional information related to future contingent payments, please read Note 19, Commitments and Contingencies to these condensed consolidated financial statements.
As of September 30, 2014, we had no accumulated impairment losses related to goodwill.

14

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, continued)

6.
Fair Value Measurements
The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:
(In millions)
As of
September 30,
2014
 
Quoted Prices
in Active
Markets
(Level 1)
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Cash equivalents
$
663.3

 
$

 
$
663.3

 
$

Marketable debt securities:
 
 
 
 
 
 
 
Corporate debt securities
774.4

 

 
774.4

 

Government securities
1,085.0

 

 
1,085.0

 

Mortgage and other asset backed securities
187.0

 

 
187.0

 

Marketable equity securities
0.7

 
0.7

 

 

Venture capital investments
16.7

 

 

 
16.7

Derivative contracts
42.9

 

 
42.9

 

Plan assets for deferred compensation
35.2

 

 
35.2

 

Total
$
2,805.2

 
$
0.7

 
$
2,787.8

 
$
16.7

Liabilities:
 
 
 
 
 
 
 
Derivative contracts
$
6.8

 
$

 
$
6.8

 
$

Contingent consideration obligations
213.2

 

 

 
213.2

Total
$
220.0

 
$

 
$
6.8

 
$
213.2

(In millions)
As of
December 31,
2013
 
Quoted Prices
in Active
Markets
(Level 1)
 
Significant
Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
Assets:
 
 
 
 
 
 
 
Cash equivalents
$
424.7

 
$

 
$
424.7

 
$

Marketable debt securities:
 
 
 
 
 
 
 
Corporate debt securities
439.8

 

 
439.8

 

Government securities
674.7

 

 
674.7

 

Mortgage and other asset backed securities
131.4

 

 
131.4

 

Marketable equity securities
11.2

 
11.2

 

 

Venture capital investments
21.9

 

 

 
21.9

Derivative contracts
3.8

 

 
3.8

 

Plan assets for deferred compensation
22.7

 

 
22.7

 

Total
$
1,730.2

 
$
11.2

 
$
1,697.1

 
$
21.9

Liabilities:
 
 
 
 
 
 
 
Derivative contracts
$
23.5

 
$

 
$
23.5

 
$

Contingent consideration obligations
280.9

 

 

 
280.9

Total
$
304.4

 
$

 
$
23.5

 
$
280.9

There have been no impairments of our assets measured and carried at fair value during the three and nine months ended September 30, 2014. In addition, there were no changes in valuation techniques or transfers between fair value measurement levels during the three and nine months ended September 30, 2014. During the three months ended September 30, 2014, we updated the probabilities of success related to the early stage programs acquired through our recent acquisitions. We have adjusted the value of our contingent consideration liabilities to reflect these changes. For additional information, please read Note 5, Intangible Assets and Goodwill to these condensed consolidated financial statements. The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third party pricing services.

15

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, continued)

For a description of our validation procedures related to prices provided by third party pricing services, refer to Note 1, Summary of Significant Accounting Policies: Fair Value Measurements, to our consolidated financial statements included within our 2013 Form 10-K.
Marketable Equity Securities and Venture Capital Investments
Our marketable equity securities represent investments in publicly traded equity securities. Our venture capital investments, which are all Level 3 measurements, include investments in certain venture capital funds, accounted for at fair value, that primarily invest in small privately-owned, venture-backed biotechnology companies. These venture capital investments represented approximately 0.1% and 0.2% of total assets as of September 30, 2014 and December 31, 2013, respectively.
The following table provides a roll forward of the fair value of our venture capital investments, which includes Level 3 measurements:
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
(In millions)
2014
 
2013
 
2014
 
2013
Fair value, beginning of period
$
21.1

 
$
23.5

 
$
21.9

 
$
20.3

Unrealized gains included in earnings
0.3

 
3.8

 
5.3

 
10.5

Unrealized losses included in earnings
(3.8
)
 

 
(5.1
)
 
(2.0
)
Purchases

 
0.3

 

 
0.3

Settlements
(0.9
)
 

 
(5.4
)
 
(1.5
)
Fair value, end of period
$
16.7

 
$
27.6

 
$
16.7

 
$
27.6

 Debt Instruments
The fair and carrying values of our debt instruments, which are Level 2 liabilities, are summarized as follows:
 
As of September 30, 2014
 
As of December 31, 2013
(In millions)
Fair
Value
 
Carrying
Value
 
Fair
Value
 
Carrying
Value
Notes payable to Fumedica
$
13.0

 
$
12.0

 
$
17.5

 
$
15.8

6.875% Senior Notes due March 1, 2018
637.9

 
575.2

 
647.9

 
580.1

Total
$
650.9

 
$
587.2

 
$
665.4

 
$
595.9

The fair value of our notes payable to Fumedica was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair value of our 6.875% Senior Notes was determined through market, observable, and corroborated sources. For additional information related to our debt instruments, please read Note 12, Indebtedness to our consolidated financial statements included within our 2013 Form 10-K.
Contingent Consideration Obligations
The following table provides a roll forward of the fair values of our contingent consideration obligations which includes Level 3 measurements:
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
(In millions)
2014
 
2013
 
2014
 
2013
Fair value, beginning of period
$
279.1

 
$
281.0

 
$
280.9

 
$
293.9

Additions

 

 

 

Changes in fair value
(49.4
)
 
(0.1
)
 
(46.2
)
 
(3.0
)
Payments
(16.5
)
 
0.1

 
(21.5
)
 
(9.9
)
Fair value, end of period
$
213.2

 
$
281.0

 
$
213.2

 
$
281.0

As of September 30, 2014 and December 31, 2013, approximately $193.9 million and $251.9 million, respectively, of the fair value of our total contingent consideration obligations were reflected as components of other long-term liabilities within our condensed consolidated balance sheets with the remaining balances reflected as a component of accrued expenses and

16

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, continued)

other. For additional information related to the changes in fair value, please read Note 5, Intangible Assets and Goodwill to these condensed consolidated financial statements.
7.
Financial Instruments
Marketable Securities
The following tables summarize our marketable debt and equity securities:
As of September 30, 2014 (In millions)
Fair
Value
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Amortized
Cost
Available-for-sale:
 
 
 
 
 
 
 
Corporate debt securities
 
 
 
 
 
 
 
Current
$
196.3

 
$
0.1

 
$

 
$
196.2

Non-current
578.1

 
0.6

 
(0.6
)
 
578.1

Government securities
 
 
 
 
 
 
 
Current
478.7

 
0.1

 

 
478.6

Non-current
606.3

 
0.4

 
(0.2
)
 
606.1

Mortgage and other asset backed securities
 
 
 
 
 
 
 
Current
0.1

 

 

 
0.1

Non-current
186.9

 
0.2

 
(0.1
)
 
186.8

Total marketable debt securities
$
2,046.4

 
$
1.4

 
$
(0.9
)
 
$
2,045.9

Marketable equity securities, non-current
$
0.7

 
$
0.2

 
$

 
$
0.5

As of December 31, 2013 (In millions)
Fair
Value
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Amortized
Cost
Available-for-sale:
 
 
 
 
 
 
 
Corporate debt securities
 
 
 
 
 
 
 
Current
$
100.7

 
$

 
$

 
$
100.7

Non-current
339.1

 
0.4

 
(0.1
)
 
338.8

Government securities
 
 
 
 
 
 
 
Current
519.5

 

 

 
519.5

Non-current
155.2

 

 
(0.1
)
 
155.3

Mortgage and other asset backed securities
 
 
 
 
 
 
 
Current

 

 

 

Non-current
131.4

 

 
(0.1
)
 
131.5

Total marketable debt securities
$
1,245.9

 
$
0.4

 
$
(0.3
)
 
$
1,245.8

Marketable equity securities, non-current
$
11.2

 
$
8.7

 
$

 
$
2.5

The following table summarizes our financial assets with maturities of less than 90 days from the date of purchase included within cash and cash equivalents on the accompanying condensed consolidated balance sheet:
(In millions)
As of
September 30,
2014
 
As of
December 31,
2013
Commercial paper
$
19.4

 
$
1.2

Overnight reverse repurchase agreements
209.2

 
22.4

Short-term debt securities
434.7

 
401.1

Total
$
663.3

 
$
424.7

The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, and our short-term debt securities approximate fair value due to their short term maturities.

17

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, continued)

Summary of Contractual Maturities: Available-for-Sale Securities
The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:
 
As of September 30, 2014
 
As of December 31, 2013
(In millions)
Estimated
Fair Value
 
Amortized
Cost
 
Estimated
Fair Value
 
Amortized
Cost
Due in one year or less
$
675.1

 
$
675.0

 
$
620.2

 
$
620.2

Due after one year through five years
1,262.0

 
1,261.8

 
573.1

 
572.9

Due after five years
109.3

 
109.1

 
52.6

 
52.7

Total available-for-sale securities
$
2,046.4

 
$
2,045.9

 
$
1,245.9

 
$
1,245.8

The average maturity of our marketable debt securities available-for-sale as of September 30, 2014 and December 31, 2013 was 14 months and 13 months, respectively.
Proceeds from Marketable Debt Securities
The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
(In millions)
2014
 
2013
 
2014
 
2013
Proceeds from maturities and sales
$
625.4

 
$
617.5

 
$
1,942.9

 
$
5,025.2

Realized gains
$

 
$
0.2

 
$
0.4

 
$
6.6

Realized losses
$
(0.1
)
 
$

 
$
(0.3
)
 
$
(2.1
)
Strategic Investments
As of September 30, 2014 and December 31, 2013, our strategic investment portfolio was comprised of investments totaling $47.4 million and $56.9 million, respectively, which are included in investments and other assets in our accompanying condensed consolidated balance sheets.
Our strategic investment portfolio includes investments in marketable equity securities of certain biotechnology companies and our investments in venture capital funds accounted for at fair value which totaled $17.4 million and $33.1 million as of September 30, 2014 and December 31, 2013, respectively. Our strategic investment portfolio also includes other equity investments in privately-held companies and additional investments in venture capital funds accounted for under the cost method. The carrying value of these investments totaled $30.0 million and $23.8 million as of September 30, 2014 and December 31, 2013, respectively.
Changes in Fair Value
During the three and nine months ended September 30, 2014 and 2013, we realized a net loss recorded through income of $3.1 million and a net gain of $1.8 million, respectively, on our strategic investment portfolio as compared to net gains of $3.8 million and $7.9 million, respectively, in the prior year comparative periods.
Impairments
For the three and nine months ended September 30, 2014 and 2013, impairment charges on our marketable equity securities of certain biotechnology companies, investments in venture capital funds accounted for under the cost method and investments in privately-held companies were insignificant.

18

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, continued)

8.
Derivative Instruments
Foreign Currency Forward Contracts - Hedging Instruments
Due to the global nature of our operations, portions of our revenues are earned in currencies other than the U.S. dollar. The value of revenues measured in U.S. dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues.
Foreign currency forward contracts in effect as of September 30, 2014 and December 31, 2013 had durations of 1 to 15 months and 1 to 18 months, respectively. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.
The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues is summarized as follows:
 
Notional Amount
Foreign Currency: (In millions)
As of
September 30,
2014
 
As of
December 31,
2013
Euro
$
629.3

 
$
636.3

Canadian dollar
10.6

 
34.0

British pound sterling
20.9

 
72.3

Total foreign currency forward contracts
$
660.8

 
$
742.6

The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) within total equity reflected gains of $41.5 million and losses of $23.6 million as of September 30, 2014 and December 31, 2013, respectively. We expect all contracts to be settled over the next 15 months and any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue. We consider the impact of our and our counterparties’ credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2014 and December 31, 2013, credit risk did not change the fair value of our foreign currency forward contracts.
The following table summarizes the effect of derivatives designated as hedging instruments on our condensed consolidated statements of income:
For the Three Months Ended September 30,
Net Gains/(Losses)
Reclassified from AOCI into Operating Income
(Effective Portion)
 
Net Gains/(Losses)
Recognized into Net Income
(Ineffective Portion)
Location
 
2014
 
2013
 
Location
 
2014
 
2013
Revenue
 
$
2.9

 
$
(7.3
)
 
Other income (expense)
 
$
(0.5
)
 
$
(0.1
)
For the Nine Months Ended September 30,
Net Gains/(Losses)
Reclassified from AOCI into Operating Income
(Effective Portion)
 
Net Gains/(Losses)
Recognized into Net Income
(Ineffective Portion)
Location
 
2014
 
2013
 
Location
 
2014
 
2013
Revenue
 
$
(7.1
)
 
$
(6.1
)
 
Other income (expense)
 
$
(1.6
)
 
$
0.2


19

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, continued)

Foreign Currency Forward Contracts - Other Derivatives
We also enter into other foreign currency forward contracts, usually with one month durations, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.
The aggregate notional amount of these outstanding foreign currency contracts was $376.1 million and $273.3 million as of September 30, 2014 and December 31, 2013, respectively. Net losses of $7.7 million and $11.5 million related to these contracts were recognized as a component of other income (expense), net, for three and nine months ended September 30, 2014, respectively, as compared to a net loss of $0.2 million and a net gain of $1.3 million, respectively, in the prior year comparative periods.
Summary of Derivatives
While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities within our condensed consolidated balance sheets.
The following table summarizes the fair value and presentation in our condensed consolidated balance sheets for our outstanding derivatives including those designated as hedging instruments:
(In millions)
Balance Sheet Location
Fair Value As of September 30, 2014
Hedging Instruments:
 
 
Asset derivatives
Other current assets
$
33.1

 
Investments and other assets
$
7.8

Liability derivatives
Accrued expenses and other
$
0.2

 
Other long-term liabilities
$

Other Derivatives:
 
 
Asset derivatives
Other current assets
$
2.0

Liability derivatives
Accrued expenses and other
$
6.6

 
 
 
(In millions)
Balance Sheet Location
Fair Value As of December 31, 2013
Hedging Instruments:
 
 
Asset derivatives
Other current assets
$
0.6

Liability derivatives
Accrued expenses and other
$
23.4

Other Derivatives:
 
 
Asset derivatives
Other current assets
$
3.2

Liability derivatives
Accrued expenses and other
$
0.1

9.
Indebtedness
Credit Facility
In March 2014, our $750.0 million senior unsecured revolving credit facility expired and was not renewed.

20

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, continued)

10.
Equity
Total equity as of September 30, 2014 increased $1,810.0 million compared to December 31, 2013. This increase was primarily driven by net income attributable to Biogen Idec Inc. of $2,051.3 million and an increase in additional paid in capital resulting from our share-based compensation arrangements totaling $126.4 million, partially offset by repurchases of our common stock totaling $360.0 million.
Share Repurchases
In February 2011, our Board of Directors authorized the repurchase of up to 20.0 million shares of common stock. This authorization does not have an expiration date. During the nine months ended September 30, 2014, we repurchased approximately 1.2 million shares of common stock at a cost of $360.0 million for the purpose of share stabilization. During the nine months ended September 30, 2013, we repurchased approximately 2.0 million shares of common stock at a cost of $400.3 million.
Approximately 2.9 million shares of our common stock remain available for repurchase under the 2011 authorization.
Noncontrolling Interests
The following table reconciles equity attributable to noncontrolling interests (NCI):
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
(In millions)
2014
 
2013
 
2014
 
2013
Noncontrolling interests, beginning of period
$
3.9

 
$
0.6

 
$
0.6

 
$
2.3

Net income (loss) attributable to NCI, net of tax
(0.7
)
 

 
7.7

 

Fair value of net assets and liabilities acquired and assigned to NCI

 

 
4.0

 

Distribution to NCI

 

 
(9.1
)
 

Deconsolidation of NCI

 

 

 
(1.7
)
Noncontrolling interests, end of period
$
3.2

 
$
0.6

 
$
3.2

 
$
0.6

11.
Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:
(In millions)
Unrealized Gains (Losses) on Securities Available for Sale
 
Unrealized Gains (Losses) on Foreign Currency Forward Contracts
 
Unfunded Status of Postretirement Benefit Plans
 
Translation Adjustments
 
Total
Balance, as of December 31, 2013
$
5.6

 
$
(23.7
)
 
$
(19.6
)
 
$
10.0

 
$
(27.7
)
Other comprehensive income (loss) before reclassifications
1.4

 
57.5

 
1.3

 
(71.2
)
 
(11.0
)
Amounts reclassified from accumulated other comprehensive income (loss)
(6.5
)
 
7.3

 

 

 
0.8

Net current period other comprehensive income (loss)
(5.1
)
 
64.8

 
1.3

 
(71.2
)
 
(10.2
)
Balance, as of September 30, 2014
$
0.5

 
$
41.1

 
$
(18.3
)
 
$
(61.2
)
 
$
(38.0
)

21

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, continued)

(In millions)
Unrealized Gains (Losses) on Securities Available for Sale
 
Unrealized Gains (Losses) on Foreign Currency Forward Contracts
 
Unfunded Status of Postretirement Benefit Plans
 
Translation Adjustments
 
Total
Balance, as of December 31, 2012
$
4.2

 
$
(10.7
)
 
$
(21.7
)
 
$
(27.1
)
 
$
(55.3
)
Other comprehensive income (loss) before reclassifications
14.1

 
(12.0
)
 
3.2

 
17.2

 
22.5

Amounts reclassified from accumulated other comprehensive income (loss)
(2.9
)
 
6.4

 

 

 
3.5

Net current period other comprehensive income (loss)
11.2

 
(5.6
)
 
3.2

 
17.2

 
26.0

Balance, as of September 30, 2013
$
15.4

 
$
(16.3
)
 
$
(18.5
)
 
$
(9.9
)
 
$
(29.3
)
The following table summarizes the amounts reclassified from accumulated other comprehensive income:
(In millions)
Income Statement Location
Amounts Reclassified from Accumulated Other Comprehensive Income
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
2014
 
2013
 
2014
 
2013
Gains (losses) on securities available for sale
Other income (expense)
$
(0.1
)
 
$
0.2

 
$
10.1

 
$
4.5

 
Income tax benefit (expense)

 
(0.1
)
 
(3.6
)
 
(1.6
)
 
 
 
 
 
 
 
 
 
Gains (losses) on foreign currency forward contracts
Revenues
2.9

 
(7.3
)
 
(7.1
)
 
(6.1
)
 
Income tax benefit (expense)
(0.1
)
 

 
(0.2
)
 
(0.3
)
 
 
 
 
 
 
 
 
 
Total reclassifications, net of tax
 
$
2.7

 
$
(7.2
)
 
$
(0.8
)
 
$
(3.5
)
12.
Earnings per Share
Basic and diluted earnings per share are calculated as follows:
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
(In millions)
2014
 
2013
 
2014
 
2013
Numerator:
 
 
 
 
 
 
 
Net income attributable to Biogen Idec Inc.
$
856.9

 
$
487.6

 
$
2,051.3

 
$
1,405.0

Denominator:
 
 
 
 
 
 
 
Weighted average number of common shares outstanding
236.2

 
237.1

 
236.6

 
237.1

Effect of dilutive securities:
 
 
 
 
 
 
 
Stock options and employee stock purchase plan
0.1

 
0.2

 
0.1

 
0.4

Time-vested restricted stock units
0.5

 
0.7

 
0.5

 
0.7

Market stock units
0.2

 
0.3

 
0.2

 
0.3

Dilutive potential common shares
0.8

 
1.2

 
0.8

 
1.4

Shares used in calculating diluted earnings per share
237.0

 
238.3

 
237.4

 
238.5

Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.

22

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, continued)

13.
Share-based Payments
Share-based Compensation Expense
The following table summarizes share-based compensation expense included within our condensed consolidated statements of income:
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
(In millions)
2014
 
2013
 
2014
 
2013
Research and development
$
24.2

 
$
20.7

 
$
78.1

 
$
69.6

Selling, general and administrative
34.7

 
39.9

 
115.5

 
119.5

Subtotal
58.9

 
60.6

 
193.6

 
189.1

Capitalized share-based compensation costs
(2.3
)
 
(2.4
)
 
(7.5
)
 
(7.4
)
Share-based compensation expense included in total cost and expenses
56.6

 
58.2

 
186.1

 
181.7

Income tax effect
(16.6
)
 
(17.4
)
 
(55.4
)
 
(54.3
)
Share-based compensation expense included in net income attributable to Biogen Idec Inc.
$
40.0

 
$
40.8

 
$
130.7

 
$
127.4

The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
(In millions)
2014
 
2013
 
2014
 
2013
Stock options
$

 
$
0.1

 
$

 
$
0.5

Market stock units
7.1

 
12.2

 
30.2

 
27.2

Time-vested restricted stock units
28.2

 
25.3

 
86.6

 
77.2

Cash settled performance units
15.2

 
20.6

 
50.6

 
76.8

Performance units
5.7

 

 
16.0

 

Employee stock purchase plan
2.7

 
2.4

 
10.2

 
7.4

Subtotal
58.9

 
60.6

 
193.6

 
189.1

Capitalized share-based compensation costs
(2.3
)
 
(2.4
)
 
(7.5
)
 
(7.4
)
Share-based compensation expense included in total cost and expenses
$
56.6

 
$
58.2

 
$
186.1

 
$
181.7

Grants Under Share-based Compensation Plans
The following table summarizes our equity grants to employees, officers and directors under our current stock plans:
 
For the Nine Months
Ended September 30,
 
2014
 
2013
Market stock units
236,000

 
268,000

Cash settled performance shares
182,000

 
273,000

Performance units
57,000

 

Time-vested restricted stock units
437,000

 
708,000


23

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, continued)

The market stock units (MSUs) granted during the nine months ended September 30, 2014 primarily vest in three equal annual increments beginning on the anniversary of the grant date. For these grants, the performance multiplier is derived based on the stock price growth rate between the 30 calendar day average closing stock price on the grant date and the 30 calendar day average closing stock price leading up to and including each of the three vesting dates. These awards may ultimately earn between 0% and 200% of the target number of units granted based on actual stock performance. Any performance multiplier less than 50% results in no shares being earned for that respective tranche.
During the first quarter of 2014, we began granting performance-vested restricted stock units (PUs), which can be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of the Board of Directors. PUs awarded to employees vest in three equal annual increments beginning on the anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31st of each year. Participants may ultimately earn between 0% and 200% of the target number of units granted based on the degree of actual performance metric achievement, with no units being earned if the performance multiplier is below 50%. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. Settlement of PUs is based on the 30 calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known.
In addition, for the nine months ended September 30, 2014, approximately 150,000 shares were issued under our employee stock purchase plan compared to approximately 208,000 shares issued in the prior year comparative period.
14.
Income Taxes
For the three and nine months ended September 30, 2014, our effective tax rate was 24.2% and 25.8% respectively, as compared to 27.4% and 22.5%, respectively, in the prior year comparative periods.
A reconciliation between the U.S. federal statutory tax rate and our effective tax rate is summarized as follows:
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
 
2014
 
2013
 
2014
 
2013
Statutory rate
35.0
 %
 
35.0
 %
 
35.0
 %
 
35.0
 %
State taxes
1.2

 
2.5

 
1.2

 
3.7

Taxes on foreign earnings
(9.3
)
 
(6.6
)
 
(8.9
)
 
(7.7
)
Credits and net operating loss utilization
(0.6
)
 
(2.2
)
 
(0.8
)
 
(3.0
)
Purchased intangible assets
0.7

 
1.9

 
1.1

 
1.6

Manufacturing deduction
(2.0
)
 
(2.5
)
 
(1.9
)
 
(8.0
)
Other permanent items
0.4

 
(0.3
)
 
0.4

 
1.0

Other
(1.2
)
 
(0.4
)
 
(0.3
)
 
(0.1
)
Effective tax rate
24.2
 %
 
27.4
 %
 
25.8
 %
 
22.5
 %
For the three months ended September 30, 2014, compared to the same period in 2013, the decrease in our income tax rate was due to a higher percentage of our income being earned outside the U.S. and an adjustment to our deferred tax liabilities to reflect a change in the effective tax rate of one of our subsidiaries, offset by a net adjustment to reflect the settlement of certain uncertain tax positions and the accrual of an uncertain tax position related to our transfer pricing items.
For the nine months ended September 30, 2014, compared to the same period in 2013, the increase in our income tax rate was primarily the result of a 2013 change in our uncertain tax position related to our U.S. federal manufacturing deduction and our unconsolidated joint business described below, lower current year expenses eligible for the orphan drug credit, partially offset by a higher percentage of our 2014 income being earned outside the U.S.
The change in the state taxes, manufacturing deduction and other permanent items of the effective tax rate reconciliation for the periods disclosed in the table above is primarily related to changes in the valuation of our federal and state uncertain tax positions in 2013, as discussed below under "Accounting for Uncertainty in Income Taxes".

24

Table of Contents
BIOGEN IDEC INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited, continued)

Accounting for Uncertainty in Income Taxes
We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in the U.S. federal jurisdiction, various U.S. states, and foreign jurisdictions. With few exceptions, including the proposed disallowance we discuss below, we are no longer subject to U.S. federal tax examination for years before 2010 or state, local, or non-U.S. income tax examinations for years before 2004.
Federal Uncertain Tax Positions
During 2013, we received updated technical guidance from the IRS concerning the calculation of our U.S. federal manufacturing deduction and overall tax classification of our unconsolidated joint business for the current and prior year filings. Based on this guidance we reevaluated the level of our unrecognized benefits related to uncertain tax positions, and recorded a $49.8 million income tax benefit. This benefit was for a previously unrecognized position and related to years 2005 through 2012. We recorded an offsetting expense of $10.3 million for non-income based state taxes, which was recorded in other income (expense) within our condensed consolidated statements of income.
In October 2011, in conjunction with our examination, the IRS proposed a disallowance of approximately $130.0 million in deductions for tax years 2007, 2008 and 2009 related to payments for services provided by our wholly owned Danish subsidiary located in Hillerød, Denmark. We believe that these items represent valid deductible business expenses. We have initiated a mutual agreement procedure between the IRS and SKAT (the Danish tax authorities) for the years 2001 through 2009, in an attempt to reach agreement on the issue. In addition, we have applied for a bilateral advanced pricing agreement for the years 2010 through 2014 to resolve similar issues for the subsequent years.
During the nine months ended September 30, 2014, the net effect of adjustments to our uncertain tax positions was a net expense of $2.1 million. It is reasonably possible that we will adjust the value of our uncertain tax positions related to our unconsolidated joint business and certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with the authorities. In addition, the IRS and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.
15.
Other Consolidated Financial Statement Detail
Other Income (Expense), Net
Components of other income (expense), net, are summarized as follows:
<
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
(In millions)
2014
 
2013
 
2014
 
2013
Interest income
$
3.6

 
$
1.5

 
$
8.7

 
$
6.7

Interest expense
(7.4
)
 
(6.6
)
 
(22.1
)
 
(25.5
)
Impairments of investments

 

 

 
(1.7
)
Gain (loss) on investments, net
(3.1
)
 
3.9

 
13.5

 
14.0

Foreign exchange gains (losses), net
(4.8
)
 
(3.1
)
 
(9.5
)
 
(11.0
)
Other, net
(4.6
)
 
(0.3
)
 
(7.6
)
 
(12.0
)